BMRN vs EDIT · P/E 40, rev $2.85B vs rev $32.3M
Biomarin Pharmaceutical Inc (BMRN) versus Editas Medicine Inc (EDIT) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. EDIT currently screens at market cap $375.2M.
Not investment advice. Open the BMRN and EDIT stock pages for the full models.
Not investment advice.